Fecal microbiome biomarkers in canine pancreatic insufficiency

Exocrine pancreatic insufficiency (EPI) is a major maldigestive disorder in dogs, commonly associated with pancreatic acinar atrophy or chronic pancreatitis. Affected dogs may present with weight loss, polyphagia, voluminous stools, flatulence and diarrhoea, although the clinical picture can vary. These signs overlap with chronic enteropathy, intestinal parasitism and other causes of altered nutrient absorption.

The topic “Fecal Microbiome as a Biomarker for Canine Exocrine Pancreatic Insufficiency” reflects growing interest in the intestinal ecosystem as a source of clinically useful information. Fecal microbial profiles may help describe disease-associated changes, treatment responses and links between digestion, fermentation and mucosal health, while established diagnostic tests remain central to patient care.

Why EPI changes the intestinal ecosystem

Reduced pancreatic enzyme delivery leaves undigested nutrients in the intestinal lumen. This altered substrate supply can influence bacterial growth, fermentation patterns and the balance between beneficial and potentially disruptive organisms. In practical terms, the microbiome may reflect the consequences of maldigestion rather than a single cause of disease.

Dogs with EPI can also have reduced microbial diversity or a shift in functional activity that resembles dysbiosis. However, a microbial signature is shaped by many variables, including diet, recent antibiotics, intestinal transit, cobalamin status, age and concurrent enteropathy. A faecal sample therefore provides valuable context, but it should not be interpreted in isolation.

Reading a faecal microbiome result

Microbiome testing may assess bacterial composition, gene pathways or metabolites such as short-chain fatty acids. The last group is particularly relevant because acetate, propionate and butyrate contribute to epithelial energy supply, immune regulation and colonic barrier function. Research on short-chain fatty acids illustrates why microbial products can be as informative as the names of individual bacterial taxa.

For veterinary teams, the most useful question is often whether a result adds information beyond clinical signs and routine testing. A single low-abundance organism is rarely a diagnosis. Patterns that remain consistent across validated studies, sample types and patient populations are more promising, particularly when combined with clinical response, serum cobalamin and pancreatic function markers.

Combining microbiome data with standard diagnosis

Serum canine trypsin-like immunoreactivity, or cTLI, remains the primary test for confirming EPI. Low cTLI supports pancreatic insufficiency, while cobalamin assessment can identify a deficiency that may require supplementation. Faecal consistency, bodyweight trends and response to pancreatic enzyme replacement provide essential clinical evidence.

Microbiome analysis may become a complementary biomarker rather than a replacement for cTLI. It could help distinguish uncomplicated EPI from cases with persistent diarrhoea, small intestinal bacterial overgrowth-like features or concurrent chronic enteropathy. This distinction matters because a dog that fails to improve may need a review of enzyme administration, diet, cobalamin status, compliance or an additional intestinal diagnosis.

Diet, treatment and sample interpretation

Diet has a strong effect on microbial composition. Fat level, fermentable fibre, protein source and digestibility can all influence the faecal profile, as can pancreatic enzyme products and antimicrobial exposure. Samples collected before treatment may not resemble those collected after stabilisation, so the timing of collection should be recorded carefully.

Australian clinicians may also need to consider the logistics of sample handling. A specimen sent from a regional Queensland practice, rural New South Wales or Western Australia to a metropolitan veterinary pathology laboratory can experience transport delays and temperature variation. Consistent collection, storage and shipping procedures are important if results are to be compared over time. Clear laboratory guidance is more useful than treating a microbiome report as a standalone score.

Clinical relevance for Australian veterinary practice

Australia’s companion animal market includes a wide range of commercial diets, prescription formulas, home-prepared meals and raw feeding patterns. Owners may describe stools as “sloppy,” “greasy” or simply “not right,” and these observations can help track response when paired with measured bodyweight and appetite. Diet history should include treats, supplements and abrupt food changes, not just the main food label.

For dogs in remote and regional communities, repeated visits and advanced testing may be less accessible than in Sydney, Melbourne or Brisbane. A practical biomarker must therefore support decisions that can be acted on locally, such as confirming the need for enzyme replacement, identifying cobalamin deficiency or prompting referral. It should also avoid overstating what a complex sequencing result can tell a busy clinic.

Research into relapse-risk modelling points towards a broader application: using microbial and clinical data together to estimate which patients may deteriorate or relapse. That approach could eventually support more individualised monitoring for dogs with overlapping EPI and chronic enteropathy.

A faecal microbiome biomarker is most credible when it is reproducible, clinically interpretable and linked to outcomes that matter to the patient. For now, it is best viewed as an expanding layer of evidence alongside cTLI, cobalamin, dietary assessment and treatment response. This integrated approach reflects the complexity of the gut microbiome while keeping diagnosis grounded in sound veterinary practice.